SCHEDULE: John Paul DeJoria Discloses 5.5% Stake in Telomir Pharma
Beneficial Ownership Disclosure
John Paul DeJoria, through his family trust and individually, has reported a 5.5% beneficial ownership stake in Telomir Pharmaceuticals, Inc.
Summary
- John Paul DeJoria, both individually and as trustee of the John Paul DeJoria Family Trust, has disclosed beneficial ownership of Telomir Pharmaceuticals, Inc. Common Stock.
- The reported stake amounts to 1,774,900 shares of Common Stock, representing 5.50% of the total class.
- DeJoria holds sole voting and sole dispositive power over all 1,774,900 beneficially owned shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The disclosure of a 5.5% beneficial ownership by a notable investor like John Paul DeJoria is generally a neutral to slightly positive signal, indicating investor interest without implying immediate operational changes or financial performance improvements.
Positives
- A significant beneficial ownership stake (5.50%) by a prominent individual like John Paul DeJoria could be interpreted as a vote of confidence in Telomir Pharmaceuticals, Inc.
- The certification that the stake is not for influencing control suggests a passive investment, which can be viewed positively by existing management.
Risks
- The filing itself does not detail specific risks related to Telomir Pharmaceuticals, Inc.'s operations or financial health; it is a disclosure of ownership.
- General market risks associated with holding equity securities apply to this investment.
Future Outlook
This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Telomir Pharmaceuticals, Inc.'s future performance or strategic direction.
Industry Context
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry. The disclosure of a significant stake by a high-profile investor like John Paul DeJoria, known for his entrepreneurial success, can sometimes draw increased attention to a company within its sector, potentially signaling perceived value or future growth prospects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | John Paul DeJoria granted a Limited Power of Attorney to Matthew R. Bair and Mate Zgombic of Egan Nelson LLP to prepare and submit SEC filings on his behalf, including Forms ID, 3, 4, 5, 13D, and 13G. | 2020-08-30 | Streamlines the process for John Paul DeJoria to comply with federal and state securities reporting requirements by delegating filing authority to legal counsel. |
Stakeholder Impact
- Shareholders: May view the significant stake by John Paul DeJoria as a positive indicator of confidence in the company's value.
- Management: The certification of a passive investment (not for control) may reassure current management.
Key Dates
| Date | Description |
|---|---|
| 2020-08-30 | Execution date of the Limited Power of Attorney by John Paul DeJoria. |
| 2025-09-09 | Date of event which required the filing of the Schedule 13G statement. |
| 2025-09-18 | Signature date of the Schedule 13G filing by Matthew R. Bair as Attorney-in-Fact. |
Keywords
Telomir Pharmaceuticals, John Paul DeJoria, Beneficial Ownership, Schedule 13G, Common Stock, Equity Stake, Pharmaceuticals, Investor Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.